title: [Variation of urinary PCA3 following transrectal ultrasound-guided prostate biopsy].
abstract: BACKGROUND
  Serum PSA is known to rise slightly following an attentive digital rectal examination (DRE) and dramatically following prostatic biopsy. The aim of this study was to evaluate the PCA3 response in these situations.
  
  
  METHODS
  In 15 consecutive men undergoing transrectal ultrasound-guided needle biopsy of the prostate and who gave their informed consent, urinary PCA3 was determined twice: at a first consultation, urine being sampled immediately after an attentive DRE and second within 2 hours after the biopsy. The mean interval between the two samplings was 14 days (median 15). PCA3 measurements were centralized and performed by the same biologist. At least twelve cores were taken using a biopsy gun with an 18-gauge needle. Changes in PCA3 levels were studied.
  
  
  RESULTS
  Mean age of the 15 men was 67.3 years (range 50.9-79.1). Mean (median) pre-biopsy total and %free PSA were respectively 6.6 ng/ml (5.7) and 15.8% (15.5). Mean prostate volume was 43.6 cm(3). Seven patients complained of mild LUTS. DRE was suspicious in eight patients. Of the 15 men, 6 (40%) had adenocarcinoma on biopsy (all clinically confined to the prostate). Median (range) Gleason score was 6 (6-7). Median PCA3 score (range) before and after prostatic biopsy were respectively 36 (9-287) and 27 (5-287) with no significant difference between the two groups (sign test for matched series p > 0.05). The median variation between pre- and post-biopsy PCA3 was -18%. When considering a PCA3 cut-off of 35, two patients changed group: one patient had 51 before and 31 after (PSA 4.6; no cancer on prostate biopsy) and the second had 36 before and 27 after (PSA 5.6; low-risk PCa). The figure represents the PCA3 values for each case (squares for the pre-biopsy and diamonds for the post-biopsy). When considering only the six patients with PCA, median (mean) PCA3 score before and after prostatic biopsy were respectively 51.5 (60.8) and 44.5 (54.8) with no significant difference between the two groups (sign test for matched series p > 0.5) and a median variation between pre- and post-biopsy PCA3 of 1.5%.
  
  
  CONCLUSIONS
  Prostate biopsy did not alter significantly urinary PCA3 value. This confirms what was theoretically expected.
authors.affiliation: Département d'urologie, centre hospitalier universitaire, Poitiers, France. yohprezelin@yahoo.fr
authors.forename: Y
authors.initials: Y
authors.lastname: Prezelin
authors.forename: C
authors.initials: C
authors.lastname: Ronsin
authors.forename: O
authors.initials: O
authors.lastname: Celhay
authors.forename: C
authors.initials: C
authors.lastname: Pirès
authors.forename: B
authors.initials: B
authors.lastname: Doré
authors.forename: G
authors.initials: G
authors.lastname: Fromont
authors.forename: S
authors.initials: S
authors.lastname: Larré
authors.forename: J
authors.initials: J
authors.lastname: Irani
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000652:urine*; D001707:Biopsy, Needle / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology* / Q000652:urine*; D012007:Rectum; D018084:Ultrasonography, Interventional
chemical_list: D000951:Antigens, Neoplasm; C479341:prostate cancer antigen 3, human